Novo Nordisk Reports Strong Q3 Results Driven by Obesity Care Growth
Novo Nordisk A/S (NVO) reported strong third-quarter results, exceeding market expectations with a 'double beat' and an upward revision of its full-year guidance. The company's growth is primarily driven by its obesity care segment, specifically the Wegovy pill, which has successfully offset declines in its diabetes business. International markets have shown stronger performance compared to the U.S. market. Financial health remains robust with adjusted operating margins rebounding to 40.1%. The company maintains strong cash flow and interest coverage. Looking forward, growth catalysts include the scaling of oral obesity treatments and the potential 2027 launch of CagriSema, positioning the company for a renewed long-term growth trajectory.
Tickers: $NVO
Topics: guidance upgrade obesity care Q3 earnings revenue growth